Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Takes Hard Line On Opioid Class REMS: Cooperate, Or Face Withdrawal

Executive Summary

FDA appears to be taking a hard line with drug sponsors on the development of a Risk Evaluation and Mitigation Strategy for extended-release opioids: cooperate on a class REMS, or face a product withdrawal
Advertisement

Related Content

Opioid Class REMS: FDA Wants Prescriber/Pharmacist Certification
FDA Kicks Off Opioid Class REMS Discussion; Asks For Industry Collaboration
FDA Kicks Off Opioid Class REMS Discussion; Asks For Industry Collaboration
Record-Setting REMS: FDA’s Classwide Opioid Program Will Be “Massive”

Topics

Advertisement
UsernamePublicRestriction

Register

PS050809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel